California Blue Shield to no longer pay for Avastin in breast cancer
This article was originally published in Scrip
Executive Summary
Joining some of its sister health insurance companies, California Blue Shield, which insures about 3.2 million people, said breast cancer will no longer be a covered indication for Genentech's Avastin (bevacizumab) as of 17 October.